Pacer Advisors Inc. Reduces Position in DaVita Inc. $DVA

Pacer Advisors Inc. reduced its holdings in shares of DaVita Inc. (NYSE:DVA) by 99.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,847 shares of the company’s stock after selling 624,942 shares during the quarter. Pacer Advisors Inc.’s holdings in DaVita were worth $438,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in DVA. Arrowstreet Capital Limited Partnership increased its stake in DaVita by 114.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after purchasing an additional 636,191 shares during the last quarter. Norges Bank acquired a new stake in DaVita in the 4th quarter valued at approximately $49,164,000. Corient Private Wealth LLC raised its stake in DaVita by 1,493.1% during the 4th quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock valued at $40,706,000 after acquiring an additional 335,809 shares in the last quarter. Man Group plc boosted its position in DaVita by 1,608.6% during the 2nd quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after acquiring an additional 269,081 shares during the period. Finally, Voloridge Investment Management LLC boosted its position in DaVita by 2,905.7% during the 3rd quarter. Voloridge Investment Management LLC now owns 228,221 shares of the company’s stock worth $30,324,000 after acquiring an additional 220,628 shares during the period. Institutional investors own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Zacks Research cut shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Raymond James Financial set a $220.00 price target on shares of DaVita in a research report on Friday. UBS Group increased their price objective on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Oppenheimer set a $220.00 price target on shares of DaVita in a report on Friday. Finally, Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $221.75.

Insider Transactions at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the transaction, the insider owned 109,194 shares in the company, valued at $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 1.90% of the stock is owned by insiders.

DaVita Trading Down 3.0%

Shares of NYSE:DVA opened at $178.25 on Wednesday. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $247.49. The firm has a fifty day moving average price of $218.11 and a 200 day moving average price of $178.10. The stock has a market capitalization of $11.37 billion, a PE ratio of 14.59, a P/E/G ratio of 0.61 and a beta of 0.88.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, sell-side analysts forecast that DaVita Inc. will post 14.57 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.